An interventional study of Sciton SkinTyte (800-1800 nm) with Broadband Light Technology in Aging, sponsored by Stanford University. Completed at 1 site in United States. Open to female participants aged 55 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-10-01.
Sponsored by Stanford University · Not applicable, Interventional, and Other
In this exploratory study, we hope to learn if treatment of broadband light with infrared light can alter the molecular pathways associated with aging. Secondary exploratory objective is to see if there are any visible effects of this light treatment on human skin.
Studies in model organisms suggest that aged cells can be functionally rejuvenated, but whether this concept applies to human skin is unclear. Recently, we applied 3'-end sequencing for expression quantification ("3-seq") to discover the gene expression program associated with human photoaging and intrinsic skin aging (collectively termed "skin aging"), and the impact of broadband light (BBL) treatment. We found significant changes in 2,265 coding and noncoding RNAs, of which 1,293 that became "rejuvenated" after BBL treatment, whereby they became more similar to their expression level in youthful skin. Rejuvenated genes (RGs) included several known key regulators of organismal longevity and their proximal long noncoding RNAs. Hence, BBL treatment can restore gene expression pattern of photo-aged and intrinsically aged human skin to resemble young skin.
However, the duration of these effects and the potential to augment these effects through increases in particular wavelengths of light have not been explored. The Sciton SkinTyte (800-1800nm) is the ideal technology to examine these questions, since this device has been used in the clinical setting to reduce cheek and submental laxity (Gold, 2010). It incorporates the broadband light technology with an emphasis on 590 nm filter to achieve these clinical results.
This study will be conducted in accord with Declaration of Helsinki principles. After Institutional Review Board approval and informed consent is obtained, six female participants over the age of 55 years will undergo BBLST treatments to the left forearm. Inclusion criteria included Fitzpatrick skin type II or III, and a global assessment of forearm skin aging consistent with moderate or severe forearm skin aging (modified validated instrument from McKenzie et al., 2011) for treated participants. Treatments will be performed on the Sciton Joule Platform using BBL in Skintyte mode with 590ST filter. On a separate part of the arm that is clearly marked, Skintyte alone will be applied. Untreated areas will also be marked. All markings will be photographed. The same investigator will perform the treatments at 4-week intervals for a total of 3 treatments. At each treatment session, two or more passes were performed. Four weeks after the third BBL treatment, 4 mm skin biopsies will performed by Keys punch technique from the BBLST treated, ST treated and adjacent untreated skin. These specimens will be bisected and placed into either RNAlater (Ambion Cat# AM7022) or formalin solution for with H\&E, von Giesen or PAS staining.
Stanford University is the lead sponsor of 2,117 studies on the registry; 425 are open to participants now.
Of its 259 completed or terminated interventional studies of FDA-regulated products, 197 (76%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
All patients will receive Skintyte treatment as well as Skintyte plus broadband light
Device: Sciton SkinTyte (800-1800 nm) with Broadband Light Technology
This device has been used in the clinical setting to reduce cheek and submental laxity. SkinTyte delivers sequentially pulsed light (800-1200 nm, with a filter enabling focus on 590 nm) and broadband light (which can be turned on or off).
Number of Genes With Significant Change in Gene Transcription
The endpoint consisted of clinical inspection of biopsies of untreated skin and skin after three treatments. Genes were considered altered if a statistically significant change in transcription of an individual gene was observed between the treated and untreated skin (significance was set at p\<0.01, adjusted for false discovery rate). The values in the table represent the total number of recorded genes with significant change.
Time frame: 16 weeks
Change From Baseline in Fine Wrinkling Score as a Measure of Skin Rejuvenation
Wrinkling was assessed on a 10 point Likert scale (range 1-10); higher scores correspond to more wrinkling.
Time frame: Baseline, day 84
Change From Baseline in Coarse Wrinkling Score as a Measure of Skin Rejuvenation
Wrinkling was assessed on a 10 point Likert scale (range 1-10); higher scores correspond to more wrinkling.
Time frame: Baseline, day 84
Change From Baseline in Sagging Score as a Measure of Skin Rejuvenation
Sagging was assessed on a 10 point Likert scale (range 1-10); higher scores correspond to more sagging.
Time frame: Baseline, day 84
Change From Baseline in Physician Global Assessment as a Measure of Skin Rejuvenation
Physician global assessment was assessed on a 10 point Likert scale (range 1-10); higher scores correspond to more severe skin aging.
Time frame: Baseline, day 84
Change From Baseline in Cutometry as a Measure of Skin Rejuvenation
Elasticity of skin assessment with cutometric probe.
Time frame: Baseline, day 84
Change From Baseline in Transepidermal Water Loss as a Measure of Skin Rejuvenation
Transepidermal water loss assessment with VapoMeter.
Time frame: Baseline, day 84
| Milestone | Skintyte |
|---|---|
| Started | 5 |
| Completed | 5 |
| Not completed | 0 |
The endpoint consisted of clinical inspection of biopsies of untreated skin and skin after three treatments. Genes were considered altered if a statistically significant change in transcription of an individual gene was observed between the treated and untreated skin (significance was set at p\<0.01, adjusted for false discovery rate). The values in the table represent the total number of recorded genes with significant change.
| genes | BBL + SPL590 vs Untreated | SPL800 (SkinTite 2) vs Untreated |
|---|---|---|
| Number of Genes With Significant Change in Gene Transcription | 188 | 45 |
Wrinkling was assessed on a 10 point Likert scale (range 1-10); higher scores correspond to more wrinkling.
| score on a scale | BBL + SPL590 | SPL800 |
|---|---|---|
| Baseline | 7.8 ± 1.89 | 7.5 ± 3.70 |
| Day 84 | 5.0 ± 3.46 | 5.3 ± 3.20 |
Wrinkling was assessed on a 10 point Likert scale (range 1-10); higher scores correspond to more wrinkling.
| score on a scale | BBL + SPL590 | SPL800 |
|---|---|---|
| Baseline | 5.0 ± 3.65 | 6.0 ± 1.83 |
| Day 84 | 2.3 ± 2.63 | 2.5 ± 1.73 |
Sagging was assessed on a 10 point Likert scale (range 1-10); higher scores correspond to more sagging.
| score on a scale | BBL + SPL590 | SPL800 |
|---|---|---|
| Baseline | 7.0 ± 1.63 | 7.5 ± 1.91 |
| Day 84 | 3.5 ± 1.73 | 4.3 ± 2.06 |
Physician global assessment was assessed on a 10 point Likert scale (range 1-10); higher scores correspond to more severe skin aging.
| score on a scale | BBL + SPL590 | SPL800 |
|---|---|---|
| Baseline | 8.3 ± 0.96 | 8.3 ± 1.50 |
| Day 84 | 5.5 ± 2.08 | 6.0 ± 1.83 |
Elasticity of skin assessment with cutometric probe.
No measurements were reported for this outcome.
Transepidermal water loss assessment with VapoMeter.
No measurements were reported for this outcome.
Collected over Up to 16 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| BBL + SPL590 | 0/5 (0%) | 0/5 (0%) | 0/5 (0%) |
| SPL800 | 0/5 (0%) | 0/5 (0%) | 0/5 (0%) |
| Untreated | 0/5 (0%) | 0/5 (0%) | 0/5 (0%) |
| Age, Continuous(years) | Skintyte |
|---|---|
| Mean | 67.6 ± 6.5 |
| Sex: Female, Male(Participants) | Skintyte |
|---|---|
| Female | 5 |
| Male | 0 |
| Ethnicity (NIH/OMB)(Participants) | Skintyte |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 5 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Skintyte |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 5 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
Documents are hosted by the registry — open the source record to download them.
Plan to share: No
This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Stanford University